CLINICAL TRIALS PROFILE FOR GLUCOTROL XL
✉ Email this page to a colleague
All Clinical Trials for GLUCOTROL XL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00032474 ↗ | Ginkgo Biloba Extract and the Insulin Resistance Syndrome | Completed | National Center for Complementary and Integrative Health (NCCIH) | Phase 1/Phase 2 | 2001-12-01 | The purpose of this study is to examine whether the ingestion of the herbal dietary supplement Ginkgo biloba extract has any effect on the efficacy of three classes of diabetic medications - (Glucotrol, Glucophage and Actose). Additionally, the study will examine the effect of Ginkgo biloba extract on pancreatic insulin production in non-diabetic subjects between the ages of 20 and 75 years old. |
| NCT00350779 ↗ | Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-12 | A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy. |
| NCT00509236 ↗ | Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-10-19 | The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control. |
| NCT00509262 ↗ | Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-10-09 | The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency. |
| NCT00550329 ↗ | Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets | Completed | Pfizer | 2007-10-01 | The objective of this study is to determine the bioequivalence of Glipizide GITS (Glucotrol XL) 2.5 mg tablets manufactured at the Brooklyn, New York facility versus tablets manufactured at the facility in Barceloneta, Puerto Rico. | |
| NCT00660907 ↗ | Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients | Completed | Bristol-Myers Squibb | Phase 3 | 2008-03-01 | This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment. |
| NCT00660907 ↗ | Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients | Completed | AstraZeneca | Phase 3 | 2008-03-01 | This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GLUCOTROL XL
Condition Name
Clinical Trial Locations for GLUCOTROL XL
Trials by Country
Clinical Trial Progress for GLUCOTROL XL
Clinical Trial Phase
Clinical Trial Sponsors for GLUCOTROL XL
Sponsor Name
